A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION
    1.
    发明授权
    A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION 有权
    方法对于抗体功能分子进化

    公开(公告)号:EP1268801B1

    公开(公告)日:2004-06-23

    申请号:EP01925538.9

    申请日:2001-04-04

    摘要: The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the 'master framework'), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the 'original framework'), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.

    METHOD OF MAKING LIBRARIES OF ANTI-LIGANDS
    2.
    发明公开
    METHOD OF MAKING LIBRARIES OF ANTI-LIGANDS 审中-公开
    用于生产的抗配体图书馆

    公开(公告)号:EP1470225A1

    公开(公告)日:2004-10-27

    申请号:EP03734721.8

    申请日:2003-01-30

    发明人: OHLIN, Mats

    IPC分类号: C12N15/10 C12N15/13

    摘要: The invention relates to methods of making anti-ligand libraries, which anti-ligands have a cavity binding site. The method comprises providing a plurality of anti-ligands having a cavity for binding a ligand, said plurality of anti-ligands being derived from a first anti-ligand having a cavity for binding a first ligand and differing from the first anti-ligand in that one or more of the amino acid residues which make up the ligand binding surface of the cavity are varied whereby the plurality of anti-ligands have a binding affinity for a first ligand which is different from that of the first anti-ligand, and wherein the one or more amino acid residues which is varied, is varied by replacement with one amino acid having similar but different physicochemical properties to the one or more amino acid residues, and wherein the one or more amino acids being varied can be varied to become a different amino acid in each anti-ligand molecule being varied. Preferably the anti-ligands are antibodies or fragments thereof which are capable of forming a cavity which can bind a ligand.

    A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION
    3.
    发明公开
    A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF ANTIBODY FUNCTION 有权
    方法对于抗体功能分子进化

    公开(公告)号:EP1268801A2

    公开(公告)日:2003-01-02

    申请号:EP01925538.9

    申请日:2001-04-04

    摘要: The present invention provides a method for producing a polynucleotide sequence encoding an antibody variable domain, the variable domain comprising complementarity-determining regions (CDRs) located within a selected framework (the 'master framework'), the method comprising the steps of (a) providing at least one nucleic acid molecule encoding one or more CDRs and associated framework regions (the 'original framework'), (b) amplifying at least one CDR-encoding portion of the nucleic acid molecule(s) of step (a) using one or more pairs of oligonucleotides as amplification primers and (c) assembling a polynucleotide sequence encoding an antibody variable domain by combining the amplified CDR-encoding nucleotide sequences produced in step (b) with nucleotide sequences encoding said master framework, wherein the oligonucleotide primers of step (b) comprise nucleotide sequences which differ from the corresponding nucleotide sequences encoding said master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.